Free Trial

PainReform (PRFX) Competitors

PainReform logo
$1.49 +0.02 (+1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$1.49 +0.00 (+0.07%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PRFX vs. AIMD, BTAI, CYCN, ATNF, LIXT, NKGN, PHXM, KZIA, SNSE, and IMNN

Should you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Ainos (AIMD), BioXcel Therapeutics (BTAI), Cyclerion Therapeutics (CYCN), 180 Life Sciences (ATNF), Lixte Biotechnology (LIXT), NKGen Biotech (NKGN), PHAXIAM Therapeutics (PHXM), Novogen (KZIA), Sensei Biotherapeutics (SNSE), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry.

PainReform vs. Its Competitors

PainReform (NASDAQ:PRFX) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, PainReform and PainReform both had 1 articles in the media. PainReform's average media sentiment score of 1.87 beat Ainos' score of 0.63 indicating that PainReform is being referred to more favorably in the media.

Company Overall Sentiment
PainReform Very Positive
Ainos Positive

PainReform has higher earnings, but lower revenue than Ainos. Ainos is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PainReformN/AN/A-$14.59M-$147.33-0.01
Ainos$20K540.51-$14.86M-$6.45-0.40

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PainReform
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ainos
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

37.3% of PainReform shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 10.4% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PainReform has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500.

PainReform's return on equity of 0.00% beat Ainos' return on equity.

Company Net Margins Return on Equity Return on Assets
PainReformN/A N/A N/A
Ainos N/A -88.07%-48.60%

Summary

PainReform beats Ainos on 8 of the 11 factors compared between the two stocks.

Get PainReform News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRFX vs. The Competition

MetricPainReformMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.96M$2.50B$5.70B$9.51B
Dividend YieldN/A1.75%4.69%4.01%
P/E Ratio-0.019.0528.0720.05
Price / SalesN/A757.64448.5799.42
Price / CashN/A165.2136.2258.56
Price / Book0.725.168.665.87
Net Income-$14.59M$30.99M$3.25B$258.55M
7 Day Performance2.76%7.74%4.20%2.23%
1 Month Performance15.50%16.18%10.82%12.76%
1 Year Performance-2.49%-1.03%34.70%19.36%

PainReform Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRFX
PainReform
0.7939 of 5 stars
$1.49
+1.4%
N/A-8.1%$2.96MN/A-0.014
AIMD
Ainos
1.5558 of 5 stars
$2.64
-4.7%
N/A-24.0%$11.61M$20K-0.4140High Trading Volume
BTAI
BioXcel Therapeutics
3.964 of 5 stars
$1.89
-1.0%
$42.60
+2,154.0%
-90.8%$11.57M$2.27M-0.1490Gap Up
CYCN
Cyclerion Therapeutics
2.5328 of 5 stars
$3.37
-4.8%
N/A-8.5%$11.36M$2M-2.9130Positive News
ATNF
180 Life Sciences
1.0568 of 5 stars
$2.81
+49.5%
N/A-5.3%$11.35MN/A-0.197Positive News
Earnings Report
Gap Up
High Trading Volume
LIXT
Lixte Biotechnology
N/A$3.92
-3.4%
N/A+79.7%$10.90MN/A-2.704Gap Down
NKGN
NKGen Biotech
0.5901 of 5 stars
$0.24
flat
N/A-83.8%$10.79MN/A-0.05N/AGap Down
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58MN/A0.0049
KZIA
Novogen
4.0194 of 5 stars
$8.97
-11.6%
$14.00
+56.1%
-44.7%$10.22M$1.51M0.0012Positive News
SNSE
Sensei Biotherapeutics
4.6537 of 5 stars
$7.71
-1.7%
$90.00
+1,067.3%
-47.8%$9.89MN/A-0.3440
IMNN
Imunon
1.9458 of 5 stars
$0.56
+1.4%
$15.50
+2,667.9%
-58.4%$9.68M$500K-0.4130Stock Split

Related Companies and Tools


This page (NASDAQ:PRFX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners